Search CLPT
ClearPoint Neuro, Inc.
Nasdaq · CIK 1285550
Last close10.9
Daily change-0.55 (-4.80%)
10 Years gain+73.02%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CLPT · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
52.8Momentum
4.4Acceleration
42.6Confidence
75.0Annual Revenue16
Quarterly Revenue47
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth22.0 / 25
Quality12.9 / 25
Capital Efficiency3.0 / 20
Balance Sheet9.9 / 15
Shareholder Economics1.0 / 10
Forward Indicators4.0 / 5
Signals
Gross margin expansionGross margin improved by 1.6497 percentage points.
ROIC expansionROIC improved by 17.0621 percentage points.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 9.1269 percentage points.
Heavy share dilution · HIGHDiluted share count increased 8.8305%.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM27.97%OK
Revenue CAGR 3Y21.62%OK
Gross Margin62.36%OK
Operating Margin-72.24%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-90.82%OK
Incremental Operating Margin 3Y-62.97%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y8.83%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $36.97M | $22.69M | -$24.16M | n/a | n/a | 61.38% | -65.36% | n/a | -46.34% | 28.32M |
| 2025 FY Dec 31, 2024 | $31.39M | $19.12M | -$19.73M | -$8.95M | -$9.23M | 60.92% | -62.87% | -29.39% | -235.02% | 27.03M |
| 2024 FY Dec 31, 2023 | $23.96M | $13.61M | -$22.45M | -$13.72M | -$14.44M | 56.83% | -93.7% | -60.27% | -205.32% | 24.61M |
| 2023 FY Dec 31, 2022 | $20.55M | $13.53M | -$16.33M | -$16.17M | -$16.42M | 65.84% | -79.47% | -79.9% | -186.89% | 24.18M |
| 2022 FY Dec 31, 2021 | $16.30M | $11.12M | -$13.37M | -$12.70M | -$12.87M | 68.24% | -82.05% | -78.93% | -261.72% | 20.73M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $41.08M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-330842, 0001193125-25-270123 |
| Revenue Growth TTM | 27.97% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-330842, 0001193125-25-270123 |
| Revenue CAGR 3Y | 21.62% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-111231 |
| Revenue CAGR 5Y | 23.58% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-111231 |
| Gross Profit CAGR 3Y | 18.81% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-111231 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-330842, 0001193125-25-270123 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 62.36% | Gross Profit / Revenue | OK | 0001193125-26-330842, 0001193125-25-270123 |
| Operating Margin | -72.24% | Operating Income / Revenue | OK | 0001193125-26-330842, 0001193125-25-270123 |
| ROIC | -90.82% | NOPAT / Average Invested Capital | OK | 0001193125-26-330842, 0001193125-25-270123 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-330842 |
| Current Ratio | 4.74x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.58x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-330842 |
| Revenue per Diluted Share | $1.36 | Revenue / Diluted Shares | OK | 0001193125-26-330842, 0001193125-25-270123 |